ATP Release Drives Inflammation with Lysophosphatidylcholine

Area of Science:

• Biochemistry
• Immunology
• Neuroscience

Background:

• Lysophosphatidylcholine (LPC) is a key lipid in oxidized LDL, implicated in atherosclerosis and neurodegeneration.
• LPC activates inflammatory responses in macrophages, neurons, and endothelial cells.
• The precise mechanism of LPC-induced inflammation is not fully understood.

Purpose of the Study:

• To elucidate the mechanism by which LPC promotes inflammation.
• To investigate the role of extracellular ATP in LPC-mediated inflammatory responses.

Main Methods:

• Assessed inflammatory cytokine production and cytotoxicity in response to LPC.
• Utilized ATP-hydrolyzing enzyme (apyrase) and purinergic signaling inhibitors.
• Evaluated macrophage phenotypes (IL-12p70, phagocytosis, costimulation).
• Investigated LPC-induced inflammation in vivo.

Main Results:

• LPC-induced inflammatory cytokine production and cytotoxicity depend on ATP release.
• Caspase-1-mediated IL-1β release is reduced by apyrase and purinergic inhibitors.
• Released ATP induces a specific macrophage phenotype (IL-12p70hi, low phagocytic, poorly costimulatory) independently of caspase-1.
• Apyrase treatment reduced in vivo inflammatory cytokine production.

Conclusions:

• LPC-induced inflammation involves the release of extracellular ATP.
• Extracellular ATP signaling is a critical mediator of LPC's pro-inflammatory effects.
• Targeting ATP release or purinergic signaling may offer therapeutic strategies for LPC-driven inflammatory diseases.